Shattuck Labs (NasdaqGS:STTK) Earnings Call Presentation

Company Overview - Shattuck Labs is a clinical-stage biotechnology company focused on developing novel therapeutics for inflammatory and immune-mediated diseases[5] - The lead program, SL-325, is a potential first-in-class blocking antibody targeting DR3 for the treatment of inflammatory bowel disease (IBD)[5] - The company had $86.1 million in cash and cash equivalents as of September 30, 2025, with a cash runway expected to last into 2029[5] SL-325 Program and TL1A/DR3 Pathway - SL-325 has picomolar binding affinity (1.3 pM) to DR3 and overlaps the TL1A binding site[44] - SL-325 is designed for potent DR3 blockade and does not bind to DcR3[44] - Preclinical data suggests SL-325 blocks TL1A binding at lower concentrations than benchmark anti-TL1As, with approximately 10-fold greater potency in vitro[52] - In non-human primate studies, SL-325 achieved full and durable receptor occupancy (RO) at all dose levels for at least four weeks post-dose[60] Market and Milestones - Worldwide inflammatory bowel disease (IBD) sales are expected to reach $33.3 billion by 2030[22, 76] - Enrollment is ongoing in a Phase 1 clinical trial evaluating SL-325 in healthy volunteers, with completion expected in Q2 2026[5, 76]